Avilar Therapeutics to Present In Vivo Non-Human Primate Data on ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation
WALTHAM, Massachusetts–(BUSINESS WIRE)–Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, announced today that it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022.
The presentation will include pharmacokinetic (PK) and pharmacodynamic (PD) data from single and repeated dose studies in non-human primates with monovalent ATAC degraders dosed subcutaneously and intravenously that target immunoglobulin G (IgG), an abundant extracellular protein.
Details of the presentation are as follows:
Title: ASGPR-targeted chimeras (ATACs): In vitro and In vivo Demonstration of the breakdown of extracellular proteins
Poster number: 1011
Presenting author: Alison Davis, PhD, Director of Biology
Date and time poster session: Monday, November 7, 2022, 7:30 PM-10:00 PM PT
The poster will be available on the Avilar website on Monday, November 7.
About Avilar Therapeutics
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar is developing ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that transport disease-causing proteins from the circulation to the endolysosome, where the unwanted proteins are broken down. Avilar has built a proprietary ATAC platform that includes novel, high affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs that can be extended across the extracellular proteome to a wide variety of proteins involved in the pathogenesis of human disease. Avilar leverages the ATAC platform to create a broad and diverse pipeline of first-class extracellular protein degraders. Avilar was founded and funded by RA Capital Management and is based in Waltham, MA. For more information, visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.